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A major attraction of biotechnology for investors has been the allure of new
market opportunities and the prospect of revolutionary medical, food, and
other products that will change our lives. However, biotechnology’s critics have
long expressed concern that the unpredictability of the effects of such changes
are reasons for prudence and caution. In spite of some false starts, unrealistic
expectations, and unfulfilled promises, recombinant DNA biotechnology is now
maturing as an important discipline that will underpin much of our biological
research and development during the next century. Surprising to some is the
important role of agricultural biotechnology to not only the food and feed
industry, but also to the chemical, pharmaceutical, environmental, and energy
industries, as new products are emerging in these marketplaces.
Agricultural biotechnology is beginning to act as a matchmaker for some
unexpected marriages between sectors. The National Agricultural Biotech-
nology Council’s (NABC) eighth annual meeting — Agricultural Biotechnology:
Novel Products and New Partnerships — held at Rutgers, The State University
of New Jersey, New Brunswick, New Jersey on June 4–7, 1996, debated the
social, ethical, economic, research, development, and commercialization issues
and opportunities that the new products of biotechnology pose for consumers,
farmers, industry, public interest groups, government, and universities. Asked
to be provocative and to speculate, 14 plenary speakers from the public and the
food, pharmaceutical, and environmental and energy sectors set the stage for
intensive workshop discussions of the social and ethical issues raised by new
products and the opportunities for structural and economic changes.
Following the plenary sessions, participants in three workshops tackled a set
of tough questions from the viewpoints of the food industry, the pharmaceutical
industry, and the environmental and energy sector.
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PLENARY SESSION HIGHLIGHTS
PLENARY SESSION I: NOVEL PRODUCTS AND NEW PARTNERSHIPS
Kenneth Barton, Vice President for Research, Agracetus, was one of the two
keynote speakers. His talk, “Biotechnology: Catalyst for Change in Agricul-
ture,” set the stage by pointing out how the application of biotechnology will
help to sustain population growth and food production on the earth’s finite area
of cultivable land. The increased speed and great breadth of current change,
along with the relevance of biotechnology to industries other than agriculture,
will significantly impact progress in this field. He pointed to the current ac-
celeration of the transition from biotechnology development to product and
market development and the unprecedented scope of recent introductions to
the marketplace. Barton went on to review the important role that intellectual
property protection will continue to have in shaping the biotechnology industry
in years to come. The speed of developments in biotechnology was illustrated
by the progress made in improving the strength of cotton fibers, with a single
genetic engineering step responsible for a strength increase equivalent to that
achieved in 30 years of classical plant breeding.
As a counterpoint to the brave new world of biotechnology, the other key-
note speaker, Rebecca Goldburg, Senior Scientist, Environmental Defense Fund,
spoke of the unknown environmental impacts of biotechnology. She explained
the skepticism of the environmental community over promises that fertilizers
and pesticides would be replaced by crops that fix their own nitrogen and
protect themselves from pests and diseases and benefit the environment. The
first have not materialized and engineered resistance has yet to have a signifi-
cant effect in reducing pesticide applications. She described those claims as
greenwashing. In her view, bioremediation has been oversold and pollution
prevention will be far more effective in dealing with the problems caused by
chemical wastes. Goldburg also expressed continuing concern over the hazards
that might result from gene transfer between the growing range of engineered
plants and animals and their wild and cultivated relatives. She cited the many
examples of escapes from aquaculture facilities, pointing to added risk of trans-
genic fish to wild populations. And she stressed the importance of conditions
attached to recent permits issued by the EPA that can lead to the cancellation
of permits. Those conditional registrations represent a step toward the kind of
innovative regulations the environmental community seeks to have in place.
Together, the keynote speakers demonstrated the open sharing of diverse
views that has become the hallmark of the NABC conferences.
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PLENARY SESSION II: CREATING NEW MARKET OPPORTUNITIES FOR
AGRICULTURAL BIOTECHNOLOGY
David Evans, Executive Vice-President, DNA Plant Technology Corporation,
described the commercial opportunities for tomatoes that stay firm and fresh
longer (ethylene-regulated tomatoes, for example, now have a shelf-life of
somewhere between 40 and 90 days.) He reviewed the seven different tech-
nologies that must be used to achieve this result, noting that all of them are
governed by various intellectual property claims that limit a company’s ability
to commercialize new developments. He underscored the potential impact upon
the industry of this increasingly complex and interwoven state of intellectual
property rights, citing the challenge of balancing possible obstacles to inno-
vation with companies’ need to exert control over intellectual property.
From the pharmaceutical industry, Dianne Defuria, Director of Commercial
Development, Bristol Myers-Squibb, discussed the role of industrial-scale plant
cell culture technology in relieving her company of its dependence on extract-
ing the anti-cancer drug paclitaxel from the bark of Pacific Yew, which at first
was peeled by hand from the trunk and major limbs in natural stands. Interest-
ing issues of high technology facilitating conservation of trees arise from this
sort of situation.
Jeff Gain, Chair of the Board of the Alternative Agricultural Research and
Commercialization (AARC) Corporation of the USDA, represented the Environ-
mental and Energy sector and discussed industrial uses of agricultural products.
He stressed the difficulties in growing industrial hemp without cyclone fences,
guard towers, and search lights!
Caron Chess, Director of the Center for Environmental Communications,
Rutgers University, discussed the public’s interest in agricultural biotechnology
and their perceptions of risk. She reviewed the importance of how information
is supplied, pointing to the fallacy of the overly simplistic idea that if you give
people information it will change their attitude and, in turn, their behavior.
Information does not make people agree with what scientific experts might call
“rational.” An array of additional factors enter into their formation of opinions.
PLENARY SESSION III: SOCIAL ISSUES, REGULATIONS, AND ETHICS
The first speaker, Sister Miriam MacGillis, Director of Genesis Farm, presented
a point of view completely opposed to biotechnology as well as other inter-
ventions by humans in natural processes. She voiced her concern about world
hunger, presenting a view that the lawlessness of the global market system is
responsible for the crises of modern society. Her thesis is that an obsession with
genetic engineering may bring about a total undermining of the life that bio-
technology is committed to redesigning.
In a provocative juxtaposition of presentations, Charles Arntzen, President/
CEO, Boyce Thompson Institute, devoted his presentation to the utilization
of biotechnology for fighting disease among children in lesser developed
countries. He gave an account of some successful research on the expression
of antigenic proteins in transgenic plants that may make it possible to raise
vaccines in plants against hepatitis B, bacterial and viral diarrheal disease, and
other infections. The objective of this work is to create an oral vaccine that is
delivered when the transgenic food plant that expresses it is consumed. The
plant of choice is the banana because its fruit is eaten raw and it is a widely
accessible and acceptable food in many lesser developed countries.
Ken Evans, President of the Arizona Farm Bureau, described the application
of other modern technologies and spoke of his own use of a 300 horsepower
sludge injection tractor remotely controlled by a portable computer. Using
sensitive biotechnology-based tests to detect and reject loads contaminated
with toxic materials and disease organisms, he has applied over three million
metric tons of uncontaminated municipal biosolids during the last 18 years,
raising the elevation of his 22 square-mile ranch by over three inches! Clearly
a believer in the proactive adoption of suitable technologies, Evans predicted
that industrial and chemical feedstock production will be a major source of
revenue for future farmers, who will be as comfortable on the Internet as
yesterday’s farmers were using a shovel. He stressed, however, that innovative
farming must be done with provision for recreational land use and improved
environmental management.
Martine Kraus of the Center for the Study of Law and Society, University
of California, Berkeley, described the importance of regulation that assists
the development of the biotechnology industry without stifling innovation.
A comparison of the experience of United States and German biotechnology
companies was revealing as shown by Germany’s 20-fold higher regulatory
costs. Whereas regulation creates a known climate for companies and assures
consumer confidence, it was reassuring to note her conclusion that innovation
thrives independent of the regulatory framework.
PLENARY SESSION IV: ECONOMIC AND STRUCTURAL ISSUES
The session began with a talk by Brewster Kneen, an agricultural journalist
from British Columbia, who discussed the biases and assumptions implied
in the expression “food industry.” Stripped of its hyperbole, Kneen reduced
biotechnology to a monoculture modeled on the production line. Drawing an
analogy between the safety of automobiles and of biotechnology, he highlighted
our ability to ignore or eliminate what doesn’t fit or what is unknown, and our
preoccupation with speed and precision.
Julian Cooper, of PPL Therapeutics, spoke of the value to the pharmaceutical
industry of proteins produced in transgenic animals. He used as an example the
attachment of a milk gene promoter to a gene encoding a therapeutic protein.
The latter is expressed in the mammary gland of the animal so that the trans-
genic protein can be harvested and purified from its milk with no adverse
effects on the animal. Many therapeutic proteins are modified after translation
from DNA in order to be therapeutically active in ways that bacterial expression
systems, for example, cannot handle. A case in point is the inability of bacterial
systems to add sugar residues to proteins (glycosylation). The yields of trans-
genic proteins from mammalian tissue culture systems are low, and the costs
of establishing them are high, making production by farm animals an attractive
mechanism for providing some important pharmaceuticals.
In his talk about the use of plants to remove heavy metals from contaminated
soil, Burt Ensley, CEO of Phtyotech Inc., spoke about the novel blending of
agriculture with the environmental industry. The best results have been ob-
tained with selected forms of an agronomic crop, Indian Mustard, that take up
and concentrate toxic metals from contaminated soils. When the plants with
high concentrations of metal are harvested, the biomass of plant debris from
a contaminated site is only about two percent of the original mass of contami-
nated soil, decreasing disposal costs while leaving cleaned topsoil in place. The
harvested plants can be composted or incinerated to further concentrate the
toxic metals. He showed experiments in progress on lead contaminated land in
the inner city of Trenton, N.J., where the objective was to render the site safe
for other uses in a way that can be perceived by the community as “natural”
and “environmentally friendly.”
The final plenary paper, by Marylou Garr of the Ontario Federation of Agri-
culture, presented biotechnology from a farmer’s perspective. She described the
evolution over the last three years of the Ontario Agricultural Biotechnology
Committee. This group was designed to promote knowledge and understanding
within the agricultural industry, to improve communication within the agri-
cultural community and between it and society at large, to influence future re-
search and commercialization, and to encourage assessment of and access
to biotechnology products for Ontario. Because the rate of discovery of new
products is far more rapid than our ability to address the issues that each raises,
the committee is already performing a valuable function at the intersection of
research and development with farming and the public.
In between the plenary sessions, participants joined one of three workshops.
While the plenary sessions described here were designed to stimulate contro-
versy, the real heart of the meeting lay in the dialogues arising in the work-
shops. In those breakout sessions, participants explored implications of
Creating New Market Opportunities; Social Issues, Regulations, and Ethics;
and Economic, and Structural Issues for a particular industry sector. Lively
debate coupled with mutual respect ran throughout those sessions. The
workshop reports begin on page 23.
Those attending the Food Industry Workshop discussed the pathways to
be taken by new food products, issues of communication, regulation, and
consumer concern over food, and the ways in which the production of new
food crops might impact the structure of the agricultural and food industries.
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